Brief: X4 Pharmaceuticals’Presentations At ASH 2022 Highlight Opportunity For Its Neutropenia Drug

X4 Pharmaceuticals

12/12/2022 13:57

Dec 12 (Reuters) - X4 Pharmaceuticals Inc  XFOR.O :
    * X4 PHARMACEUTICALS’ PRESENTATIONS AT ASH 2022 FURTHER
HIGHLIGHT
OPPORTUNITY FOR MAVORIXAFOR IN THE TREATMENT OF CHRONIC
NEUTROPENIA
    * X4 PHARMACEUTICALS INC - ORAL PRESENTATION DETAILS
POSITIVE DATA
FROM MAVORIXAFOR PHASE 1B CLINICAL TRIAL IN CHRONIC IDIOPATHIC,
CYCLIC, OR CONGENITAL NEUTROPENIA

Source text for Eikon:  ID:nGNX9RWW8G 
Further company coverage:  XFOR.O 
 ((Reuters.Briefs@thomsonreuters.com;))